Glutathione levels and variability in breast tumors and normal tissue

GSH appears to be a marker of breast malignancy that is independent of hormonal receptor status and stage and may be a marker of cells with increased potential for dissemination. Because of tumor heterogeneity, multiple sites should be sampled whenever possible. Long-term clinical follow-up will be necessary to ascertain the usefulness of tumor and lymph node GSH levels in predicting prognosis.